Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $25.8 million.

  • SAB Biotherapeutics' Net Cash Flow rose 41741.16% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 20475.92%. This contributed to the annual value of -$47.4 million for FY2024, which is 21427.89% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Net Cash Flow stood at $25.8 million for Q3 2025, which was up 41741.16% from -$2.1 million recorded in Q2 2025.
  • SAB Biotherapeutics' Net Cash Flow's 5-year high stood at $54.1 million during Q4 2023, with a 5-year trough of -$42.5 million in Q1 2024.
  • Moreover, its 5-year median value for Net Cash Flow was -$2.1 million (2025), whereas its average is $887000.8.
  • In the last 5 years, SAB Biotherapeutics' Net Cash Flow surged by 3384108.16% in 2021 and then plummeted by 203929.35% in 2024.
  • SAB Biotherapeutics' Net Cash Flow (Quarter) stood at $28.8 million in 2021, then crashed by 76.68% to $6.7 million in 2022, then surged by 706.03% to $54.1 million in 2023, then tumbled by 99.97% to $15539.0 in 2024, then soared by 165740.97% to $25.8 million in 2025.
  • Its Net Cash Flow stands at $25.8 million for Q3 2025, versus -$2.1 million for Q2 2025 and -$3.3 million for Q1 2025.